Medzown utilizes an AI-powered platform and Precision Medicine Scientists to rapidly match patients with optimal treatments and clinical trials. This service accelerates patient access to personalized care options while providing healthcare providers with curated, evidence-backed recommendations. The platform delivers significant cost savings for health plans by optimizing high-cost member spend through data-driven treatment selection.
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with cancer and complex diseases often lack timely access to cutting-edge treatments and relevant clinical trials after failing standard of care or when no standard of care exists. Navigating the complex landscape of available therapies and clinical trial enrollment can be challenging for both patients and their physicians.
Solution
Medzown offers precision medicine management services that leverage advanced analytics to connect patients with cancer and complex or rare diseases to appropriate treatments, including immunotherapies, targeted therapies, cell and gene therapies, and clinical trials. By bridging the gap between patients and advanced therapies, Medzown aims to improve patient outcomes and streamline access to the "right" therapies. The company provides patients and their care teams with strategies to evaluate treatment options and clinical trials, along with support to navigate clinical trial enrollment and adherence. Medzown's approach also delivers a return on investment for payers, providers, and pharmaceutical companies.
Target Audience
Medzown's primary customers include patients with cancer and complex or rare diseases, their physicians, payers, employers, and pharmaceutical companies.
Features
- Advanced analytics to match patients with appropriate treatments and clinical trials
- Strategies for patients and care teams to evaluate treatment options
- Support for navigating clinical trial enrollment and adherence
- Streamlined access to advanced therapies, including immunotherapies, targeted therapies, and cell and gene therapies